On Thursday, a Vermont legislative panel resumed its review of a bill which would legallyize psilocybin within the state. The bill also established a work group to discuss how to regulate psychedelics further for therapeutic purposes.
The Senate Health and Welfare Committee did not take any formal action on S.114. However, the members heard testimony and indicated their willingness to make a few changes to the proposal. This included removing the legalization part and making it an issue that the workgroup would study.
Ginny (D), chair of the committee, said: “It’s possible that decriminalization will get in the path of therapeutic use.” What we are looking at is the value of therapeutic uses.
Some other possible changes were suggested by legislators during the hearing, such as changing the composition of the working group. For example, Lyons suggested that the members of the Vermont legislature be removed and a representative of the University of Vermont’s Medical School added.
The panel will also include representatives of Johns Hopkins University School of Medicine and the Office of Professional Regulation of Maryland, as well as the advocacy group Decriminalize Nature.
The legislation, as introduced, would remove psilocybin’s name from the list of state-prohibited drugs, legalizing psychedelic mushrooms.
The report also calls for the creation of a Psychedelic Treatment Advisory Working group that will be responsible for “examining the use of psychedelics in order to improve mental and physical health, and making recommendations about the establishment of a state program”, similar to those being implemented in Oregon or Colorado.
legislators on the House side considered a companion H.371, bill during a House Judiciary Committee Hearing last May.
Charles MacLean (associate dean of primary medicine at the University of Vermont) gave an overview of the science and history of psychedelics during the Senate hearing on Thursday.
He also presented the results of an online survey conducted by hundreds of Vermont primary care doctors. The doctors responded that psychedelics were generally considered to be medically promising, if not overhyped. They also believed they weren’t particularly harmful for one’s own health. The majority of respondents expressed concern about the increased risk to driving and youth access.
In particular, 56 percent of respondents believe that psychedelics have a “high therapeutic potential,” and 40 percent are neutral. Only 4 percent disagreed.
Over three-quarters of respondents (77%) said that they would like to learn more about psychedelics. Nearly two-thirds (64%), however, said that they strongly or agreeably agreed with the idea that research into psychedelics’ risks and benefits should be given high priority.
More than 70% of the doctors surveyed (71%) expressed moderate to high concern about psychedelics use by youth. However, more than 60% (61%) were concerned with driving safety.
Only 17 percent of respondents felt that psychedelics were “detrimental to health.”
Katherine MacLean shared her experience of psilocybin with us. She studied under Roland Griffiths who was a pioneer in the field of psychedelics. Without psilocybin she says, “I don’t know if I would still be alive today.”
She said that criminalizing substances creates a risk of harm.
She told the panel that she had always been concerned about what might happen if her desire to relieve herself of pain led her to do something illegal. “It is a worry I have every day. I also know that many parents and caregivers are concerned about it. ‘”
She added, “I’d love to remove the fear and worry for people who just want to feel better.”
She also said that she has worked with victims of psychedelic abuse. She explained that her “enthusiasm” was only slightly dimmed because of these examples, and that many victims were unable to speak up.
She said that “some of these women have licenses who have been hurt, whether sexually, emotionally, or financially, by unscrupulous professionals.” They were medical doctors and therapists. They had review boards. The women should have followed the ethics of their profession but didn’t. “The women were scared to speak up because the drugs used were criminal.”
MacLean was open to this idea, but preferred to see the changes made sooner than later.
She said, “There is a certain urgency but I do not think that another year will make much of a difference.” “So, if it is smarter to do this, I think it will be considered in full. But, if the decriminalization piece can also be considered, that would be fantastic.”
Lyons, panel chair, described the feedback as “terrific” and said the panel would likely make more changes before the bill is advanced for the session.
Vermont’s House recently passed another drug-related action this session. It was a bill that legalized and funded safe consumption sites as part of a program pilot aimed at reducing the epidemic of drug-related death. This is another attempt to permit the facilities after Gov. Phil Scott (R) ‘s veto in 2022 of a measure that would have created a taskforce to develop a plan for opening the sites.
In 2024, lawmakers in the U.S. are preparing for what is already proving to be a busy year in terms of psychedelics legislation.
This week, the Arizona Senate, for instance, passed a bipartisan measure that would allow psychedelic to be administered in medically-supervised settings.
This week, a Missouri Senate committee passed a bill that would allow veterans to use psilocybin as psychedelic medicine. The bill also funds studies to explore the therapeutic potential.
Recently, the governor of New Mexico endorsed a newly passed resolution that requested state officials to research the therapeutic potential psilocybin as well as explore the creation a regulatory framework for providing access to psychedelic.
The Connecticut Joint Judiciary Committee has filed a bill that would decriminalize psilocybin.
A senator from Illinois introduced a bill to legalize and regulate access to psilocybin at service centers within the state, where adults can use the psychedelic under supervision. The program will eventually include mescaline and ibogaine.
Alaska House and Senate Committees are currently considering legislation to create a taskforce to investigate how to license, and regulate psychedelic assisted therapy. This is in anticipation of a federal legalization at some point of substances such as MDMA and Psilocybin.
Hawaii lawmakers are also advancing a bill that would provide some legal protections for patients who engage in psilocybin assisted therapy after obtaining a doctor’s approval.
New York legislators also stated that a bill that would legalize psilocybin assisted therapy in the state had a “real shot” at passing this year.
An Indiana House Committee , meanwhile , approved this week a Republican-led Bill that would fund clinical trials into psilocybin , which has already cleared the entire Senate.
Recently, bipartisan California legislators introduced a bill that would legalize psychedelic services centers, where adults aged 21 and over could have access to psilocybin MDMA mescaline DMT and other psychedelics in a supervised environment , with trained facilitators.
Last month, a joint Nevada legislative committee heard expert testimony and public testimony about the therapeutic potential for substances such as psilocybin. Law enforcement officials also expressed their concerns about legalization. However, there was a notable acknowledgment that reforms could be implemented including rescheduling.
The Governor of Massachusetts recently promoted the testimony from activists who spoke out in support of her veterans’ bill. This bill would, among other things, create a work group for psychedelics to investigate the therapeutic potentials of substances like psilocybin.
Fetterman: Excluding the military from Biden’s Marijuana pardons is a’mistake’
Photo courtesy Wikimedia/Mushroom Observer.
The original post Vermont Lawmakers consider removing psilocybin legalization provision from Psychedelic Study Group bill first appeared on Marijuana Moment.
